Abstract
Cancer is a heterogeneous disease, and sub-populations of cells can drive drug resistance. Fluorescence lifetime imaging of metabolic co-factors is used to monitor drug response on a cellular level, to optimize treatment strategies for patients.
© 2015 Optical Society of America
PDF ArticleMore Like This
Melissa C. Skala
CL_2_3 The European Conference on Lasers and Electro-Optics (CLEO/Europe) 2015
Melissa C. Skala, Alex J. Walsh, Amy T. Shah, Joseph T. Sharick, Tiffany M. Heaster, Rebecca S. Cook, Carlos L. Arteaga, Melinda E. Sanders, and Ingrid Meszoely
JW4A.1 Cancer Imaging and Therapy (Cancer) 2016
Amani Gillette, Cheri Pasch, Chris Babiarz, Dustin Deming, and Melissa Skala
OmS2D.6 Optical Molecular Probes, Imaging and Drug Delivery (OMP) 2017